InVitae Corp (NYSE:NVTA) Insider Randal W. Scott Sells 40,000 Shares

Share on StockTwits

InVitae Corp (NYSE:NVTA) insider Randal W. Scott sold 40,000 shares of the firm’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $24.59, for a total transaction of $983,600.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

NYSE:NVTA traded down $1.03 during trading hours on Tuesday, reaching $23.94. The company’s stock had a trading volume of 1,878,400 shares, compared to its average volume of 1,874,230. The firm has a market capitalization of $2.31 billion, a price-to-earnings ratio of -12.34 and a beta of 2.53. The firm has a 50-day simple moving average of $24.87 and a 200-day simple moving average of $22.04. InVitae Corp has a 1 year low of $9.04 and a 1 year high of $28.75. The company has a debt-to-equity ratio of 0.36, a quick ratio of 7.18 and a current ratio of 7.18.

InVitae (NYSE:NVTA) last issued its earnings results on Tuesday, August 6th. The medical research company reported ($0.54) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.06). The business had revenue of $53.48 million during the quarter, compared to analysts’ expectations of $50.17 million. InVitae had a negative return on equity of 58.48% and a negative net margin of 83.69%. InVitae’s revenue for the quarter was up 43.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.47) EPS. Equities analysts anticipate that InVitae Corp will post -2.11 earnings per share for the current fiscal year.

NVTA has been the subject of a number of research analyst reports. Chardan Capital set a $32.00 price objective on shares of InVitae and gave the stock a “buy” rating in a report on Sunday. Leerink Swann set a $31.00 price objective on shares of InVitae and gave the stock a “buy” rating in a report on Wednesday, August 7th. Oppenheimer set a $34.00 price objective on shares of InVitae and gave the stock a “buy” rating in a report on Wednesday, August 7th. Finally, Benchmark reaffirmed a “buy” rating and set a $28.00 price objective (up from $26.00) on shares of InVitae in a report on Wednesday, August 7th. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $28.50.

A number of large investors have recently modified their holdings of the stock. Dimensional Fund Advisors LP bought a new stake in shares of InVitae during the 4th quarter worth about $319,000. Mercer Global Advisors Inc. ADV bought a new stake in shares of InVitae during the 1st quarter worth about $2,137,000. Los Angeles Capital Management & Equity Research Inc. bought a new stake in shares of InVitae during the 1st quarter worth about $259,000. BNP Paribas Arbitrage SA boosted its stake in shares of InVitae by 86,776.5% during the 1st quarter. BNP Paribas Arbitrage SA now owns 14,769 shares of the medical research company’s stock worth $346,000 after acquiring an additional 14,752 shares in the last quarter. Finally, Bank of Montreal Can boosted its stake in shares of InVitae by 377.9% during the 1st quarter. Bank of Montreal Can now owns 77,810 shares of the medical research company’s stock worth $1,823,000 after acquiring an additional 61,528 shares in the last quarter. Institutional investors own 87.51% of the company’s stock.

About InVitae

Invitae Corporation, a genetic information company, processes DNA-containing samples, analyzes information related to patient-specific genetic variation, and generates test reports for clinicians and their patients in the United States, Canada, and internationally. Its tests include genes associated with hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders, metabolic disorders, and other hereditary conditions; and screening and testing services in reproductive health, including preimplantation and carrier screening for inherited disorders, prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders.

Further Reading: What is the definition of market timing?

Insider Buying and Selling by Quarter for InVitae (NYSE:NVTA)

Receive News & Ratings for InVitae Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InVitae and related companies with MarketBeat.com's FREE daily email newsletter.